Edap Tms SA (ADR)  

(Public, NASDAQ:EDAP)   Watch this stock  
Find more results for EDAP
3.11
-0.01 (-0.32%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.00 - 3.16
52 week 2.76 - 6.57
Open 3.15
Vol / Avg. 23,516.00/34,118.00
Mkt cap 88.35M
P/E 35.88
Div/yield     -
EPS 0.09
Shares 28.72M
Beta 1.57
Inst. own 12%
Aug 24, 2016
Q2 2016 Edap Tms SA Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 18, 2016
Q1 2016 Edap Tms SA Earnings Release
May 18, 2016
Q1 2016 Edap Tms SA Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 15.58% -5.17%
Operating margin 8.40% 1.51%
EBITD margin - 4.62%
Return on average assets - -4.71%
Return on average equity - -11.27%
Employees 165 -
CDP Score - -

Address

Parc Activite La Poudrette Lamartine 4/6 Rue du Dauphine
VAULX-EN-VELIN, 69120
France
+33-4-72153150 (Phone)
+33-4-72153151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications.

Officers and directors

Philippe Chauveau Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Marc Oczachowski Chief Executive Officer and Director
Bio & Compensation  - Reuters
Pierre Beysson Independent Director
Bio & Compensation  - Reuters
Robrecht L.W. Michiels Independent Director
Bio & Compensation  - Reuters
Argil J. Wheelock Independent Director
Age: 67
Bio & Compensation  - Reuters